Indivior has announced the discontinuation of its marketing efforts for Opvee following a settlement reached on September 29 with New York’s Office of the Attorney General. This settlement stems from an investigation into the procurement practices of a county sheriff’s office regarding the opioid overdose reversal drug, Opvee. The implications of this decision are significant for Indivior, as it not only affects the company’s market presence but also raises questions about regulatory compliance and the broader landscape of opioid-related products.
The investigation highlighted potential concerns regarding the marketing strategies employed by pharmaceutical companies in the context of opioid medications. As regulatory scrutiny intensifies, companies in the pharmaceutical sector must reassess their marketing practices to ensure alignment with evolving legal standards. This case serves as a cautionary tale for B2B professionals in regulatory, QA/QC, CMC, sourcing, and portfolio management, emphasizing the need for vigilance in compliance to avoid similar repercussions.
Start your 7-day trial and see what the database can do →
